Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers

Cover Page


Cite item

Full Text

Abstract

Aim of study. To evaluate clinical significance of different combinations of gene polymorphisms IL-1b, IL-6, IL-10, TNF, HFE, TGF-b, ATR1, NOS3894, CYBA, AGT, MTHFR, FII, FV, FVII, FXIII, ITGA2, ITGB3, FBG, PAI and their prognostic value for prediction of liver fibrosis progression rate in patients with chronic hepatitis C (CHC).

Subjects and methods: 118 patients with CHC were divided into «fast» and «slow» (fibrosis rate progression ≥0,13 and <0,13 fibrosis units/yr; n =64 and n =54) fibrosis groups. Gene polymorphisms were determined. Statistical analysis was performed using Statistica 10.

Results. A allele (p =0,012) and genotype AA (p =0,024) of AGT G-6T gene, as well as T allele (p =0,013) and MT+TT genotypes (p =0,005) of AGT 235 M/T gene were significantly more common in «fast fibrosers» than in «slow fibrosers». Patients with genotype TT of CYBA 242 C/T had a higher fibrosis progression rate than patients with CC+CT genotype (p =0,02). Our analysis showed a protective effect of TT genotype of ITGA2 807 C/T on fibrosis progression rate (p =0,03). There was a trend (p <0,15) to higher fibrosis progression rate in patients with mutant alleles and genotypes of TGFb +915 G/C, FXIII 103 G/T, PAI -675 5G/4G genes. Other gene polymorphisms were not associated with enhanced liver fibrosis. To build a mathematical model for prediction of liver fibrosis progression rate we performed coding with scores for genotypes and virus genotype. Total score correlated with the fibrosis progression rate (R =0,39, p =0,000).

Conclusion: Determination of genetic profile of the patient and virus genotype allows to predict the course of CHC.

 

About the authors

Larisa Mikhaylovna Samokhodskaia

Lomonosov Moscow State University

Email: slm@fbm.msu.ru
к.м.н., доц., Факультет фундаментальной медицины Россия

Ekaterina Evgen'evna Starostina

Lomonosov Moscow State University

Author for correspondence.
Email: starostinaee@gmail.com
аспирант, Факультет фундаментальной медицины Россия

Elena Borisovna Yarovaya

Lomonosov Moscow State University

Email: yarovaya@mech.math.msu.su
д.ф.-м.н., доц., Механико-математический факультет Россия

Tat'yana Nikolaevna Krasnova

Lomonosov Moscow State University; Sechenov First Moscow state medical university

Email: krasnovamgu@yandex.ru
к.м.н., доц., Факультет фундаментальной медицины Россия

Nikolay Alekseevich Mukhin

Lomonosov Moscow State University; Sechenov First Moscow state medical university

Email: moukhin-nephro@yandex.ru
д.м.н., проф., академик РАН, Факультет фундаментальной медицины Россия

Vsevolod Arsen'evich Tkachuk

Lomonosov Moscow State University

Email: vat@fbm.msu.ru
д.б.н., проф., академик РАН, декан ФФМ МГУ Россия

Viktor Antonovich Sadovnichy

Lomonosov Moscow State University

Email: info@rector.msu.ru
д.ф.-м.н., проф., академик РАН, ректор МГУ Россия

References

  1. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000;20(1):47−55. doi: 10.1055/s-2000-9258
  2. Самоходская ЛМ, Игнатова ТМ, Абдуллаев СМ, Краснова ТН, Некрасова ТП, Мухин НА, Ткачук ВА. Прогностическое значение комбинации аллельных вариантов генов цитокинов и гемохроматоза у больных хроническим гепатитом С. РЖГГК. 2007;17(2):50−56.
  3. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31(4):828–833. doi: 10.1053/he.2000.6253.
  4. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol.36(2):271–277. doi: 10.1016/S0168-8278(01)00243-4.
  5. Hamada H, Yatsuhashi H, Yano K, Arisawa K, Nakao K, Yano M. Interleukin-10 promoter polymorphisms and liver fibrosis progression in patients with chronic hepatitis C in Japan. J Hepatol. 2003;39(3):457−8. doi: 10.1016/S0168-8278(03)00246-0
  6. Rosen HR, McHutchison JG, Conrad AJ, Lentz JJ, Marousek G, Rose SL, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97(3):714–720. doi: 10.1111/j.1572-0241.2002.05552.x
  7. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol. 2003;71(2):212–218. doi: 10.1002/jmv.10472.
  8. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun. 2000;1(6):386–390. doi: 10.1038/sj.gene.6363696.
  9. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505–510. doi: 10.1016/j.jhep.2004.11.026.
  10. Takahara T, Fukuyama Y, Saito S, Ogino T, Miyajima N, Kohase M. Il-1, EGF, and HGF suppress the antiviral activity of interferon in primary monkey hepatic parenchymal cells. Jpn J Infect Dis. 1999;52(2):45−8.
  11. Tian Z, Shen X, Feng H, Gao B. IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J Immunol. 2000;165(7):3959–3965. doi: 10.4049/jimmunol.165.7.3959.
  12. Bahr MJ, El Menuawy M, Boeker KHW, Musholt PB, Manns MP, Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int. 2003;23(6):420–425. doi: 10.1111/j.1478-3231.2003.00873.x.
  13. Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int. 2007;27(8):1134–1143. doi: 10.1111/j.1478-3231.2007.01518.x.
  14. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55(6):362–369. doi: 10.1007/s00251-003-0594-5.
  15. Patricia KC, Marta W-S, Michael C, Anna B-K, Ian GM, Mathew EC, et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver. 2002;22(5):404–412. doi: 10.1034/j.1600-0676.2002.01553.x.
  16. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316(1–2):83–94. doi: 10.1016/s0009-8981(01)00738-0.
  17. Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Analysis of the transforming growth factor-β1 (TGF-β1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine. 2003;24(5):173–181. doi: 10.1016/j.cyto.2003.08.007.
  18. Suzuki S, Tanaka Y, Orito E, Sugauchi F, Hasegawa I, Sakurai M, et al. Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003;18(10):1139–1143. doi: 10.1046/j.1440-1746.2003.03161.x.
  19. Wang H. Transforming growth factor-β1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11(13):1929. doi: 10.3748/wjg.v11.i13.1929.
  20. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C - natural history and cofactors. Aliment Pharmacol Ther. 2005;22(s2):74–78. doi: 10.1111/j.1365-2036.2005.02602.x.
  21. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol. 2003;38(3):335–342. doi: 10.1016/s0168-8278(02)00415-4.
  22. Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 2004;24(4):285–294. doi: 10.1111/j.1478-3231.2004.0928.x.
  23. Pácal L, Husa P, Znojil V, Kan̆ková Ki. HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. Hepatol Res. 2007;37(9):740–747. doi: 10.1111/j.1872-034X.2007.00118.x.
  24. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat. 2004;11(2):175–182. doi: 10.1046/j.1365-2893.2003.00488.x.
  25. Dostalikova-Cimburova M, Kratka K, Stransky J, Putova I, Cieslarova B, Horak J. Iron Overload andHFEGene Mutations in Czech Patients with Chronic Liver Diseases. Dis Markers. 2012;32(1):65–72. doi: 10.1155/2012/790464.
  26. Forrest EH, Thorburn D, Spence E, Oien KA, Inglis G, Smith CA, et al. Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 2005;12(5):519–524. doi: 10.1111/j.1365-2893.2005.00630.x.
  27. Maharshak N. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol. 2011;17(45):5007. doi: 10.3748/wjg.v17.i45.5007.
  28. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D’Anto M, Capasso R, et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology. 2005;41(5):995–1003. doi: 10.1002/hep.20664.
  29. Wright M. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003;52(8):1206–1210. doi: 10.1136/gut.52.8.1206.
  30. Poujol-Robert A, Boëlle P-Y, Poupon R, Robert A. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology. 2004;39(4):1174–1175. doi: 10.1002/hep.20166.
  31. Goulding C, O’Brien C, Egan H, Hegarty JE, McDonald G, O’Farrelly C, et al. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source. J Viral Hepat. 2007;14(4):255–259. doi: 10.1111/j.1365-2893.2006.00790.x.
  32. Dik K, de Bruijne J, Takkenberg RB, Roelofs JJ, Tempelmans MJ, Dijkgraaf MGW, et al. Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. Hepatology Research. 2012;42(7):668–676. doi: 10.1111/j.1872-034X.2011.00963.x.
  33. Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degott C, et al. Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology. 2005;129(6):2064–2075. doi: 10.1053/j.gastro.2005.09.010.
  34. Wu G, Xi Y, Yao L, Su L, Yan Y, Li M, et al. Genetic polymorphism ofITGA2C807T can increase the risk of ischemic stroke. Int J Neurosci. 2014;124(11):841–851. doi: 10.3109/00207454.2013.879718.
  35. Armendáriz-Borunda J, Rincón AR, Muñoz-Valle JF, Bueno-Topete M, Oregón-Romero E, Islas-Carbajal MC, et al. Fibrogenic Polymorphisms (TGF-β, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment. J Investig Med. 2008;56(7):944–953. doi: 10.231/JIM.0b013e3181891512.
  36. Richardson MM. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet. 2005;42(7):e45–e45. doi: 10.1136/jmg.2005.032557.
  37. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, et al. Identification of Two Gene Variants Associated With Risk of Advanced Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology. 2006;130(6):1679–1687. doi: 10.1053/j.gastro.2006.02.032.
  38. Hissar SS, Kumar M, Tyagi P, Goyal A, Pv S, Agarwal S, et al. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J Gastroenterol Hepatol. 2009;24(4):581–587. doi: 10.1111/j.1440-1746.2008.05649.x.
  39. Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655–666. doi: 10.1016/j.jhep.2009.05.016.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies